Susquehanna International Group’s Altamira Therapeutics Ltd CYTO Stock Holding History

Susquehanna International Group’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-65	Closed	-$29K	–	14313
2022 Q1	$29K	Sell	65 -40	-38%	-$19.3K	﹤0.01%	12522
2021 Q4	$77K	Buy	+105	New	+$70.4K	﹤0.01%	12311
2021 Q3	–	Sell	-95	Closed	-$135K	–	13822
2021 Q2	$135K	Buy	95 +2	+2%	+$2.74K	﹤0.01%	11917
2021 Q1	$129K	Buy	+93	New	+$125K	﹤0.01%	11737
2017 Q1	–	Hold	0	–	-$13K	–	10237
2016 Q4	–	Hold	0	–	–	–	9460
2016 Q3	–	Hold	0	–	–	–	8150

Other funds holding CYTO

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Susquehanna International Group's CYTO Position: Q4 2023 in Review

Susquehanna International Group sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2023, closing a stake of 509 shares — an estimated $2.46K sold.

Susquehanna International Group first reported a position in CYTO in Q4 2017 and held it in 9 quarters. The position peaked at $115K in Q4 2021. 4 funds tracked by Wall St. Rank hold CYTO as of Q4 2023.

Susquehanna International Group reported no remaining Altamira Therapeutics Ltd position as of Q4 2023 after selling out during the quarter.
Susquehanna International Group sold 509 Altamira Therapeutics Ltd shares in Q4 2023, an estimated $2.46K.
Susquehanna International Group first reported a position in Altamira Therapeutics Ltd in Q4 2017 and held it in 9 quarters.
Susquehanna International Group's Altamira Therapeutics Ltd position peaked at $115K in Q4 2021.
4 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2023.

Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.